Zacks Investment Research downgraded shares of ENZYMOTEC LTD (ENZY) from NEUTRAL to UNDERPERFORM on June 13, 2014, with a target price of $12.90.
Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ENZYMOTEC LTD (ENZY),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment